Romiti, Giulio Francesco
Corica, Bernadette
Mei, Davide Antonio
Bisson, Arnaud
Boriani, Giuseppe
Olshansky, Brian
Chao, Tze-Fan
Huisman, Menno V.
Proietti, Marco
Lip, Gregory Y. H. http://orcid.org/0000-0002-7566-1626
,
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 20 September 2023
Accepted: 26 March 2024
First Online: 8 April 2024
Declarations
:
: All patients provided written informed consent. The study protocol was approved by local institutional review boards at each participating centre. The study was conducted according to the Good Clinical Practice and the Declaration of Helsinki.
: Not applicable.
: GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally. AB has been a consultant or speaker for Astra-Zeneca, Bayer, BMS/Pfizer, Medtronic, Vitorpharma and Alnylam. TFC reported honoraria for lectures from Boehringer Ingelheim, Bayer, Pfizer and Daiichi Sankyo, outside the submitted work. GB reports small speaker fees from Bayer, Boehringer Ingelheim, Boston, BMS, Daiichi, Sanofi and Janssen outside the submitted work. BO has one disclosure AstraZeneca DSMB, Consultant for Boehringer Ingelheim. MVH has been receiving research grants from the Dutch Healthcare Fund, Dutch Heart Foundation, BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim and consulting fees from BMS-Pfizer, Bayer Healthcare and Boehringer Ingelheim to the institution. All other authors have nothing to declare. MP is national leader of the AFFIRMO project on multimorbidity in atrial fibrillation, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 899871. GYHL has been consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Anthos and Daiichi-Sankyo. No fees are directly received personally. All the disclosures happened outside the submitted work. GYHL is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 899871.